Shares of Vertex soared on the news that it has inked a collaboration deal with Johnson & Johnson to develop VX-950 for hepatitis C. Vertex gains $165 million and up to $380 million in milestone payments. Vertex retains North American development rights to the drug.
- read the AP report [1]
Links:
[1] http://www.chron.com/disp/story.mpl/ap/fn/4015093.html